In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: Salutary lessons in drug commercialization

This article was originally published in Scrip

Executive Summary

Last week, personalized cancer vaccine company Dendreon appeared to be in terminal decline as it struggles with low sales of its expensive product for prostate cancer, Provenge (sipuleucel-T), in the face of cheaper, more easily administered and more efficacious competition, and also with a large debt mountain. Dendreon is a rare and, you would think, salutary event in life science investing.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts